Sufentanil citrate
USP/1623648 - United States Pharmacopeia (USP) Reference Standard
Synonym: N-
CAS Number: 60561-17-3
Empirical Formula (Hill Notation): C22H30N2O2S · C6H8O7
Molecular Weight: 578.67
Linear Formula: C22H30N2O2S · C6H8O7
Product Type: Chemical
API family | sufentanil |
application(s) | pharmaceutical (small molecule) |
drug control | USDEA Schedule I; regulated under CDSA - not available from Sigma-Aldrich Canada; estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal) |
format | neat |
grade | pharmaceutical primary standard |
InChI | 1S/C22H30N2O2S.C6H8O7/c1- |
InChI key | OJCZPLDERGDQRJ-UHFFFAOYSA |
manufacturer/tradename | USP |
Analysis Note: | These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. |
Application: | Sufentanil citrate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. |
Biochem/physiol Actions: | Sufentanil is a mu-opioid selective agonist, 10 times more potent than fentanyl, over 1000 times more potent than morphine. Sufentanil citrate is used as an analgesic and anesthesia adjunct. There are some differences in activity and selectivity among the mu-opiate agonist analgesics. Receptor-internalizing agonists like beta-endorphin, methadone, fentanyl, and sufentanil have been found to induce NADH/NADPH-mediated reactive oxygen species (ROS) synthesis via Phospholipase D-dependent signaling pathways whereas agonists like morphine that do not induce receptor endocytosis failed to activate ROS synthesis. In another report meperidine, remifentanil and tramadol were found to interact with alpha(2)-adrenoceptors, whereas sufentanil did not. |
General description: | This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia . |
Other Notes: | Sales restrictions may apply. |
Symbol | GHS06 |
Signal word | Danger |
Hazard statements | H300 + H310 + H330 |
Precautionary statements | P260 - P262 - P280 - P301 + P330 + P331 + P310 - P302 + P352 + P310 - P304 + P340 + P310 |
RIDADR | UN 2811 6.1 / PGII |
WGK Germany | WGK 3 |
Flash Point(F) | Not applicable |
Flash Point(C) | Not applicable |
UNSPSC | 41116107 |